Diego Mastino1,2, Maud Robert3,4,5, Cecile Betry2,4,5, Martine Laville2,4,5, Christian Gouillat3,4,5, Emmanuel Disse6,7,8. 1. Department of Endocrinology and Metabolic disease, Institute of Internal Medicine, University of Cagliari, Monserrato, 09045, Cagliari, Italy. 2. Department of Endocrinology Diabetology and Nutrition, Groupement Hospitalier Lyon Sud, Hospices Civils de Lyon, F69495, Pierre Bénite, France. 3. Department of Digestive Surgery, Center of Bariatric Surgery, Hopital Edouard Herriot, Hospices Civils de Lyon, F69437, Lyon, France. 4. Fédération Hospitalo-Universitaire DO-IT. Centre Intégré et Spécialisé de L'Obésité de Lyon. CRNH-RA, Hospices Civils de Lyon, Lyon, France. 5. University Claude Bernard Lyon 1, Lyon, France. 6. Department of Endocrinology Diabetology and Nutrition, Groupement Hospitalier Lyon Sud, Hospices Civils de Lyon, F69495, Pierre Bénite, France. emmanuel.disse@gmail.com. 7. Fédération Hospitalo-Universitaire DO-IT. Centre Intégré et Spécialisé de L'Obésité de Lyon. CRNH-RA, Hospices Civils de Lyon, Lyon, France. emmanuel.disse@gmail.com. 8. University Claude Bernard Lyon 1, Lyon, France. emmanuel.disse@gmail.com.
Abstract
BACKGROUND: Sarcopenic obesity is the combination of low muscle mass and strength with increased fat mass. This condition is associated with negative health outcomes. We hypothesized that sarcopenia could be a pejorative factor on surgical weight loss. OBJECTIVE: The objectives of the study are to determine the influence of sarcopenic obesity on gastric bypass and sleeve gastrectomy results regarding weight loss and comorbidities resolution at 3, 6, and 12 months. SETTING: The study was conducted at the University Hospital. METHODS: Sixty-nine obese patients who benefited from bariatric surgery were included. Skeletal muscle mass was determined by the Janssen's equation. Physical performance and muscle strength were determined using the 6-min walk test and the wall sit test. Obese subjects from the lowest tertile of the Skeletal Muscle mass Index (SMI) of Baumgartner were set as sarcopenic. RESULTS: Weight loss outcomes and rate of weight loss failure were not influenced by sarcopenia. At 1 year, mean EBMIL% was 75.4 % ± 5 in sarcopenic subjects vs 67.8 % ±4 in the non-sarcopenic subjects (p = 0.242). Improvement rates of co-morbidities were similar between groups. Skeletal muscle mass was no more different between groups at 1 year after surgery. There was no patient lost to follow-up. CONCLUSIONS: Bariatric surgery remains effective in achieving weight loss target in sarcopenic patients, with similar remission rates of main comorbidities and similar safety profile than in the non-sarcopenic group. Whether bariatric surgery could result in improvement or deterioration of daily living activities disabilities and functional autonomy in sarcopenic obese patients still have to be evaluated.
BACKGROUND:Sarcopenic obesity is the combination of low muscle mass and strength with increased fat mass. This condition is associated with negative health outcomes. We hypothesized that sarcopenia could be a pejorative factor on surgical weight loss. OBJECTIVE: The objectives of the study are to determine the influence of sarcopenic obesity on gastric bypass and sleeve gastrectomy results regarding weight loss and comorbidities resolution at 3, 6, and 12 months. SETTING: The study was conducted at the University Hospital. METHODS: Sixty-nine obesepatients who benefited from bariatric surgery were included. Skeletal muscle mass was determined by the Janssen's equation. Physical performance and muscle strength were determined using the 6-min walk test and the wall sit test. Obese subjects from the lowest tertile of the Skeletal Muscle mass Index (SMI) of Baumgartner were set as sarcopenic. RESULTS:Weight loss outcomes and rate of weight loss failure were not influenced by sarcopenia. At 1 year, mean EBMIL% was 75.4 % ± 5 in sarcopenic subjects vs 67.8 % ±4 in the non-sarcopenic subjects (p = 0.242). Improvement rates of co-morbidities were similar between groups. Skeletal muscle mass was no more different between groups at 1 year after surgery. There was no patient lost to follow-up. CONCLUSIONS: Bariatric surgery remains effective in achieving weight loss target in sarcopenic patients, with similar remission rates of main comorbidities and similar safety profile than in the non-sarcopenic group. Whether bariatric surgery could result in improvement or deterioration of daily living activities disabilities and functional autonomy in sarcopenic obesepatients still have to be evaluated.
Authors: T N Kim; S J Yang; H J Yoo; K I Lim; H J Kang; W Song; J A Seo; S G Kim; N H Kim; S H Baik; D S Choi; K M Choi Journal: Int J Obes (Lond) Date: 2009-06-30 Impact factor: 5.095
Authors: S J Baek; G E Nam; K D Han; S W Choi; S W Jung; A R Bok; Y H Kim; K S Lee; B D Han; D H Kim Journal: J Endocrinol Invest Date: 2014-01-09 Impact factor: 4.256
Authors: Seung Ha Park; Jae Hee Park; Pil Sang Song; Dong Kie Kim; Ki Hun Kim; Sang Hoon Seol; Hyun Kuk Kim; Hang Jea Jang; Jung Goo Lee; Ha Young Park; Jinse Park; Kyong Jin Shin; Doo il Kim; Young Soo Moon Journal: J Am Soc Hypertens Date: 2013-07-30
Authors: Arnaud Sans; Laurent Bailly; Rodolphe Anty; Igor Sielezenef; Jean Gugenheim; Albert Tran; Philippe Gual; Antonio Iannelli Journal: Obes Surg Date: 2017-11 Impact factor: 4.129